Chengdu Taihe Health Technology Group Inc., Ltd. (Stock Code: 000790, hereinafter referred to as Taihe Health) was listed on the Shenzhen Stock Exchange in 1998 (according to the strategic development needs, the Company name was changed from “Chengdu Huasun Group Co., Ltd.” to “Chengdu Taihe Health Technology Group Inc., Ltd.” in September 2016). It is a high-tech enterprise specialized in Chinese and Western medicines, bio-pharmaceuticals and building steel structures. There are one branch and four wholly-owned subsidiaries affiliated to Taihe Health – Huasun Pharmaceutical Factory of Chengdu Taihe Health Technology Group Inc., Ltd. (hereinafter referred to as the Pharmaceutical Factory), Chengdu University of TCM Huasun Pharmaceutical Co., Ltd. (hereinafter referred to as the Pharmaceutical Company), Chengdu Huasun Biotechnology Co., Ltd. (hereinafter referred to as the Biotechnology Company), Sichuan Huasun Steel Structure Engineering Co., Ltd.(hereinafter referred to as the Steel Structure Company)
        Taihe Health Group is an innovation-driven company, which has undertaken a number of national projects from the “863 Program”, the New Product Trial Program and the National Enterprise Technology Center Innovation Program, as well as more than 50 national and provincial major science and technology projects, such as the special industrial development project of national modern Chinese medicine. It has applied for and obtained about 90 patents, including 5 international patents [PCT], providing adequate reserves of technologies, projects and products for the development of the Group. Taihe Health has cultivated a new medicine of the original national Category II TCM for the treatment of cardiovascular and cerebrovascular diseases – San qi Tongshu Capsule, a product known as one of the typical varieties for the modernization and internationalization of China’s TCM, and becoming a large variety with rapid growth of sales. Based on the bio-pharmaceutical platform, the Group has bred the world’s first McAb radio-immunity targeted drug for the treatment of primary hepatocellular carcinoma (HCC) – the national Category I new drug “Licartin” Iodine [131I]Metuximab Injection, known as the human “biological missile”, and the in vitro diagnostic kit for coronary heart disease –“Guan Xin” Oxidized Low Density Lipoprotein Detection Kit (ELISA). 
        After years of market exploration and promotion, Taihe Health Group has steadily improved its operating capacity in the pharmaceutical market, increased the sales year by year, and developed largely mature sales network resources. The Group always adheres to the “academic marketing” strategy, and has owned a sound sales system and a high-quality, young, professional and responsive academic marketing team; basically established a national drug sales network, covering most provincial capitals and major secondary cities at home, and built good cooperative relations with more than 1,000 hospitals.
     In the future, Taihe Health Group will always take “Enhance the quality of life   Pass love and responsibility” as a corporate mission, and strive to build a domestic first-class and internationally renowned big health industry group that relies on modern Chinese medicine, features biopharming, and integrates pharmaceutical manufacturing, medical services and health regimen.